Monoclonal Antibodies In Veterinary Health Market Report 2026

Monoclonal Antibodies In Veterinary Health Market Overview

• Monoclonal Antibodies In Veterinary Health market size has reached to $0.92 billion in 2025 • Expected to grow to $1.85 billion in 2030 at a compound annual growth rate (CAGR) of 14.8% • Growth Driver: Rising Animal Disease Incidences Drive Growth Of Monoclonal Antibodies In Veterinary Health Market • Market Trend: New Monoclonal Antibody Treatments For Osteoarthritis In Pets • North America was the largest region in 2025.

What Is Covered Under Monoclonal Antibodies In Veterinary Health Market?

Monoclonal antibodies in veterinary health are specialized proteins engineered to target and neutralize specific pathogens or toxins in animals, aiding in the diagnosis and treatment of various diseases. They are created by cloning a single type of immune cell to produce identical antibodies that precisely bind to their target. The main types of animals in monoclonal antibodies in veterinary health are dogs and others. A dog refers to a domesticated mammal (Canis lupus familiaris) that is commonly kept as a pet or working animal. These antibodies find applications in dermatology, pain management, and others, serving end users such as veterinary hospitals and others.

What Is The Monoclonal Antibodies In Veterinary Health Market Growth Forecast?

The monoclonal antibodies in veterinary health market size is expected to see rapid growth in the next few years. It will grow to $1.85 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to technological advancements in mAb engineering, increasing adoption of species-specific therapies, rising investment in veterinary oncology and dermatology, growth of personalized veterinary medicine, expansion of global veterinary healthcare infrastructure. Major trends in the forecast period include growth in monoclonal antibody-based canine cancer treatments, rising use of mabs for autoimmune disorders in dogs, expansion of veterinary dermatology applications, increasing adoption of targeted pain management therapies, development of species-specific antibody therapies for cats, horses, and livestock.

What Is The Driver Of The Monoclonal Antibodies In Veterinary Health Market?

The rising animal disease incidences are expected to propel the growth of the monoclonal antibodies in veterinary health market going forward. The rising incidence of animal diseases is driven by intensified farming practices, which increase the risk of infectious disease spread, and climate change, which expands the range of disease vectors such as ticks and mosquitoes. Monoclonal antibodies are highly useful for treating animal diseases as they target specific pathogens or proteins involved in disease processes, offering precise and effective treatments. For instance, in June 2024, according to a report published by the GOV.UK, a UK-based government website, between April 2023 and March 2024, the number of animals slaughtered due to TB incidents rose by 5% in England to 21,298, and by 17% in Wales to 11,197. The rising animal disease incidences are driving the growth of monoclonal antibodies in veterinary health industry.

Key Players In The Global Monoclonal Antibodies In Veterinary Health Market

Major companies operating in the monoclonal antibodies in veterinary health market are Zoetis Inc, Boehringer Ingelheim International GmbH, MSD Animal Health, Elanco Animal Health Incorporated, Heska Corporation, Ceva Santé Animale S.A., Biogénesis Bagó S.A., PetMedix Ltd, Merck & Co Inc, Virbac SA, Kindred Biosciences Inc, Dechra Pharmaceuticals, Vetigenics, Akston Biosciences Corporation, MabGenesis Inc, IDEXX Laboratories Inc, Nexvet Biopharma, Epitopix LLC, Indian Immunologicals Ltd, Vetoquinol, Phibro Animal Health, Norbrook Laboratories, AnimalCare, Eco Animal Health, Venkys, Hester Biosciences Limited, ImmuCell

Global Monoclonal Antibodies In Veterinary Health Market Trends and Insights

Major companies operating in the monoclonal antibodies in veterinary health market are focusing on developing innovative veterinary therapeutic solutions, such as anti-NGF monoclonal antibody treatment to address conditions such as chronic pain and inflammation in animals. Anti-NGF monoclonal antibody treatment refers to a therapeutic approach that targets and inhibits nerve growth factor (NGF) to reduce pain and inflammation in animals suffering from chronic pain conditions. For instance, in May 2023, Zoetis, a US-based animal health company, received FDA approvals for Librela (bedinvetmab injection), the first monoclonal antibody treatment for controlling pain associated with osteoarthritis (OA) in dogs, which is administered as a once-monthly injection, and Apoquel Chewable, the first chewable medication specifically for managing allergic itch and inflammation in dogs aged one year or older. Librela is a monoclonal antibody that targets and inhibits nerve growth factor (NGF). By blocking NGF, Librela helps to prevent these pain signals from reaching the brain, thereby reducing the sensation of pain in dogs with osteoarthritis. Librela represents a significant advancement in veterinary pain management, providing a novel approach to treating chronic pain in dogs.

What Are Latest Mergers And Acquisitions In The Monoclonal Antibodies In Veterinary Health Market?

In January 2024, Ceva Santé Animale, a France-based provider of animal health products and services, acquired Scout Bio Inc. for an undisclosed amount. With this acquisition, Ceva Santé aims to significantly enhance its global biotechnology efforts in animal health by leveraging Scout Bio's expertise in advanced therapies such as gene therapy and monoclonal antibodies, accelerating innovation to address chronic diseases in pets. Scout Bio Inc. is a US-based biotechnology company revolutionizing and developing a pipeline of monoclonal antibody therapies for chronic conditions in pets.

What Defines the Monoclonal Antibodies In Veterinary Health Market?

The monoclonal antibodies in veterinary health market consist of sales of diagnostic kits, therapeutic drugs, research reagents, monoclonal antibody drugs, and therapeutic formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Monoclonal Antibodies In Veterinary Health Market Report 2026?

The monoclonal antibodies in veterinary health market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the monoclonal antibodies in veterinary health industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.